At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 62 enrolled
Drug / intervention
Memantine (once daily) +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Interventional, Randomised, Double-blind, Study to Evaluate the Safety and Tolerability of Once Daily Versus Twice Daily Memantine Treatment in Patients With Dementia of Alzheimer's Type and MMSE Range 5 - 18
In Brief
A Phase 4 clinical trial evaluating Memantine (once daily) and Memantine (twice daily) for Alzheimer Dementia (AD). Completed, enrolled 62 participants across 6 sites.
Detailed Summary
Evaluation of the safety and tolerability of a 20 mg once daily dose of memantine compared with 10 mg given twice daily in patients with dementia of Alzheimer's type and MMSE range 5-18.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAlzheimer Dementia (AD)
CountriesChina
Collaborators--
Timeline
Phase 4CompletedFinished
20162017201820192020202120222023202420252026
First PostedSep 2015
Enrollment StartOct 2015
Primary CompletionJul 2016
TodayJul 2026
First PostedSep 18, 2015
Enrollment StartOct 1, 2015
Primary CompletionJul 1, 2016
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 10.8 years ago
Interventions
Memantine (once daily)drug
Memantine (twice daily)drug